

Bulletin from Annual General Meeting in Magle Chemoswed Holding AB (publ) held on the 26th of April 2023.

Today, on the 26th of April 2023 the annual general meeting was held in Magle Chemoswed Holding AB (publ).

A summary of the adopted resolutions follows below:

- Adoption of the Income Statement and Balance Sheet

The AGM resolved, in accordance with the Board of Directors' proposal, to adopt the income statement and the consolidated income statement, as well as the balance sheet and the consolidated balance sheet, as set out in the annual report 2022.

- Allocation of Profits

The AGM resolved, to appropriate the company's results according to the Board's proposal in the annual report. The AGM also resolved, in accordance with the Board's proposal, that no dividend be paid for 2022.

- Discharge from Liability

The AGM resolved, in accordance with the Board's proposal supported by the auditor, to discharge the members of the Board of Directors and the CEO, respectively, from liability in respect of their management of the Company's business during the financial year 2022.

- Election of the Board Members, Auditor, Fees to the Directors, and Auditor

The AGM resolved, in accordance with the proposal, that the number of Directors appointed by the general meeting shall consist of six (6) directors and no deputy director appointed by the general meeting. The AGM resolved in accordance with the proposal to re-elect Hans Henrik Lidgard, Martin Lidgard, Malin Malmsjö, Sven-Christer Nilsson, Mats Pettersson and Joel Eklund as ordinary members of the Board. It was further resolved to re-elect Hans Henrik Lidgard as chairman of the Board of Directors. All elections are for the period until the end of the next annual general meeting.

It was resolved to elect Ernst & Young AB with authorized auditor Henrik Rosengren, as the auditor of the Company until the end of the next annual general meeting.

The AGM resolved in accordance with the proposal that remuneration for the Board Members appointed by the shareholders' meeting that are not employed by the group shall amount to 100 000 SEK for the time until the end of the next annual shareholders' meeting, whereof the chairman of the board shall receive 200 000 SEK. The committee members shall receive 25 000 SEK.

The AGM resolved as proposed that the remuneration to the auditor shall be in accordance with the approved rates.

- Authorisation for the Board to issue new shares

The meeting resolved to authorise the Board to, on one or more occasions during the period until the next annual general meeting and within the limits of the articles of association, decide to increase the company's share capital through a new issue of shares, warrants, and/or convertibles.

The Board of Directors shall be able to decide on the issue of shares, warrants, and/or convertibles with or without a deviation from the shareholders' pre-emptive rights and/or with provisions for in-kind, set-off, or otherwise with conditions according to Chapter 2, Section 5 second paragraph 1–3 and 5 of the Swedish Companies Act. The total number of shares that may be issued by virtue of the authorisation must be within the limits of the share capital according to the articles of association.

For further information, please contact:

Justin Pierce, CEO

Phone: +46 (0)70 593 58 21

Email: Justin.Pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Bulletin from Annual General Meeting in Magle Chemoswed Holding AB \(publ\) held on the 26th of April 2023.](#)